Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 29

1.

Cornus officinalis Methanol Extract Upregulates Melanogenesis in Melan-a Cells.

An YA, Hwang JY, Lee JS, Kim YC.

Toxicol Res. 2015 Jun;31(2):165-72. doi: 10.5487/TR.2015.31.2.165.

2.

Melan-A/MART-1 immunity in a EWS-ATF1 translocated clear cell sarcoma patient treated with sunitinib: a case report.

Tazzari M, Palassini E, Vergani B, Villa A, Rini F, Negri T, Colombo C, Crippa F, Morosi C, Casali PG, Pilotti S, Stacchiotti S, Rivoltini L, Castelli C.

BMC Cancer. 2015 Feb 14;15:58. doi: 10.1186/s12885-015-1044-0.

3.

Fatty acid synthase inhibitors induce apoptosis in non-tumorigenic melan-a cells associated with inhibition of mitochondrial respiration.

Rossato FA, Zecchin KG, La Guardia PG, Ortega RM, Alberici LC, Costa RA, Catharino RR, Graner E, Castilho RF, Vercesi AE.

PLoS One. 2014 Jun 25;9(6):e101060. doi: 10.1371/journal.pone.0101060. eCollection 2014.

4.

Tyrosinase inhibitory activity of a glucosylated hydroxystilbene in mouse melan-a melanocytes.

Cheung FW, Leung AW, Liu WK, Che CT.

J Nat Prod. 2014 Jun 27;77(6):1270-4. doi: 10.1021/np4008798. Epub 2014 Jun 16.

5.

Comparative genomic hybridization in a case of melanoma that loses expression of S100, HMB45, Melan A and tyrosinase in metastasis.

Guo R, Wang X, Chen J, Gillies E, Fung KM, Li S, Hassell LA.

Int J Clin Exp Pathol. 2013 Dec 15;7(1):468-73. eCollection 2014.

6.

Marginal and joint distributions of S100, HMB-45, and Melan-A across a large series of cutaneous melanomas.

Viray H, Bradley WR, Schalper KA, Rimm DL, Gould Rothberg BE.

Arch Pathol Lab Med. 2013 Aug;137(8):1063-73. doi: 10.5858/arpa.2012-0284-OA.

7.

Prediction of cross-recognition of peptide-HLA A2 by Melan-A-specific cytotoxic T lymphocytes using three-dimensional quantitative structure-activity relationships.

Fagerberg T, Zoete V, Viatte S, Baumgaertner P, Alves PM, Romero P, Speiser DE, Michielin O.

PLoS One. 2013 Jul 16;8(7):e65590. doi: 10.1371/journal.pone.0065590. Print 2013.

8.

Depigmentation effect of Kadsuralignan F on melan-a murine melanocytes and human skin equivalents.

Goh MJ, Lee HK, Cheng L, Kong DY, Yeon JH, He QQ, Cho JC, Na YJ.

Int J Mol Sci. 2013 Jan 15;14(1):1655-66. doi: 10.3390/ijms14011655.

9.
10.

TCRs used in cancer gene therapy cross-react with MART-1/Melan-A tumor antigens via distinct mechanisms.

Borbulevych OY, Santhanagopolan SM, Hossain M, Baker BM.

J Immunol. 2011 Sep 1;187(5):2453-63. doi: 10.4049/jimmunol.1101268. Epub 2011 Jul 27.

11.

Identification of an HLA-DPB1*0501 restricted Melan-A/MART-1 epitope recognized by CD4+ T lymphocytes: prevalence for immunotherapy in Asian populations.

Meng Z, Wang Y, Zhang G, Ke Y, Yan Y, Wu L, Huang Q, Zeng G, Wang Y, Ying H, Jiao S.

J Immunother. 2011 Sep;34(7):525-34. doi: 10.1097/CJI.0b013e318226bd45.

12.

Crystal structures of HLA-A*0201 complexed with Melan-A/MART-1(26(27L)-35) peptidomimetics reveal conformational heterogeneity and highlight degeneracy of T cell recognition.

Douat-Casassus C, Borbulevych O, Tarbe M, Gervois N, Jotereau F, Baker BM, Quideau S.

J Med Chem. 2010 Oct 14;53(19):7061-6. doi: 10.1021/jm100683p.

13.

Identification of a public CDR3 motif and a biased utilization of T-cell receptor V beta and J beta chains in HLA-A2/Melan-A-specific T-cell clonotypes of melanoma patients.

Serana F, Sottini A, Caimi L, Palermo B, Natali PG, Nisticò P, Imberti L.

J Transl Med. 2009 Mar 24;7:21. doi: 10.1186/1479-5876-7-21.

14.

Crystallization and preliminary X-ray structural studies of a Melan-A pMHC-TCR complex.

Yuan F, Georgiou T, Hillon T, Gostick E, Price DA, Sewell AK, Moysey R, Gavarret J, Vuidepot A, Sami M, Bell JI, Gao GF, Rizkallah PJ, Jakobsen BK.

Acta Crystallogr Sect F Struct Biol Cryst Commun. 2007 Sep 1;63(Pt 9):758-60. Epub 2007 Aug 25.

15.

Immunohistochemical expression of melan-A and tyrosinase in uveal melanoma.

Fernandes BF, Odashiro AN, Saraiva VS, Logan P, Antecka E, Burnier MN Jr.

J Carcinog. 2007 Apr 20;6:6.

16.

Culture of melanoma cells in 3-dimensional architectures results in impaired immunorecognition by cytotoxic T lymphocytes specific for Melan-A/MART-1 tumor-associated antigen.

Ghosh S, Rosenthal R, Zajac P, Weber WP, Oertli D, Heberer M, Martin I, Spagnoli GC, Reschner A.

Ann Surg. 2005 Dec;242(6):851-7, discussion 858.

17.

Encapsulation into sterically stabilised liposomes enhances the immunogenicity of melanoma-associated Melan-A/MART-1 epitopes.

Adamina M, Bolli M, Albo F, Cavazza A, Zajac P, Padovan E, Schumacher R, Reschner A, Feder C, Marti WR, Oertli D, Heberer M, Spagnoli GC.

Br J Cancer. 2004 Jan 12;90(1):263-9.

18.
19.

Degeneracy of antigen recognition as the molecular basis for the high frequency of naive A2/Melan-a peptide multimer(+) CD8(+) T cells in humans.

Dutoit V, Rubio-Godoy V, Pittet MJ, Zippelius A, Dietrich PY, Legal FA, Guillaume P, Romero P, Cerottini JC, Houghten RA, Pinilla C, Valmori D.

J Exp Med. 2002 Jul 15;196(2):207-16.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk